Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas and internationally. With a market cap of $28.4 billion, the company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQV is scheduled to report its Q2 earnings before the market opens on Tuesday, July 22. Ahead of the event, analysts expect the company to report a profit of $2.50 per share, up 2.5% from a profit of $2.44 per share in the same quarter last year. The company has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on one other occasion. 

For the current year, analysts expect IQV to report an EPS of $10.70, up 4.4% from $10.25 in fiscal 2024. Moreover, the EPS is expected to rise in fiscal 2026, improving 10.6% annually to $11.83.

Over the past 52 weeks, IQV has declined 21.9%, underperforming both the S&P 500 Index's ($SPX) 11.9% rise and the Health Care Select Sector SPDR Fund’s (XLV) 7% decrease over the same period.

IQV stock fell 4% following the release of its Q1 2025 earnings on May 6. The company’s revenue came in at $3.8 billion, representing a 2.5% year-over-year increase and surpassing the Street’s estimate. However, its adjusted EPS for the quarter was $2.37, falling marginally short of the consensus estimate.

Analysts' consensus view on IQV stock is highly bullish, with an overall "Strong Buy" rating. Among 21 analysts covering the stock, 15 recommend a "Strong Buy," one suggests “Moderate Buy,” and five “Holds.” Its mean price target of $189.14 implies an upswing potential of 16.4% from the prevailing market prices.